Market research analysts at Technavio have predicted that the global asthma therapeutics market will grow steadily over the next four years and post an impressive revenue of more than USD 22 billion by 2020. Owing to the development of target specific drugs, there will be a high demand for monoclonal antibodies for the treatment of asthma. Monoclonal antibodies (mAbs) that block immunoglobulin E and specific cytokines are important in the initiation and persistence of asthmatic inflammation. Xolair was the first mAb to be approved for the treatment of allergic asthma and recorded huge sales right after approval. Since several manufacturers are currently focusing on the development of other mAbs, the forecast period will see the introduction of several new products. And owing to the better efficacy of these drugs over other small molecules, there will be an upsurge in their demand contributing to the growth of the asthma drugs market.
The Americas will account for more than 45% of the total share of the market and dominate the industry during the forecast period. The increase in pollution and the presence of a huge asthmatic population in the Latin American countries are identified to be the major factors that will augment the demand for asthmatic drugs from this region. Also, the introduction of new healthcare reforms of various countries in the region have resulted in reducing the cost of pharmaceutical drugs, providing increased access and quality of healthcare, and offer insurance coverage for individuals of all ages, which will, in turn, fuel the growth of the market in this region.
Competitive landscape and key vendors
Owing to the presence of several well established and small scale vendors, this market appears to be highly fragmented. Key players such as GSK, AstraZeneca, Boehringer Ingelheim, F.Hoffmann-La Roche, and Merck have a great product portfolio and account for the major revenue shares. The competition among vendors is intense and the leading vendors have also started acquiring small regional vendors to increase their share of the market. The coming years will witness a number of mergers and acquisitions and innovative product launches, which will further intensify the competitive environment in the market.
The leading vendors in the market are -
F. Hoffmann-La Roche
The other prominent vendors in the market are ALK-Abello, Amgen, Array BioPharma, Asmacure, Astellas Pharma, Atopix Therapeutics, Axikin Pharmaceuticals, Chiesi Farmaceutici, Dynavax Technologies, Horizon Pharma, Hovione Scientia, Invion, Ivax, Kissei Pharmaceutical, Kyowa Hakko Kirin, MediciNova, Mitsubishi Tanabe Pharma, Mundipharma, Nycomed, Oxagen Limited, Palobiofarma, Pearl Therapeutics, Pharmaking, Pharmaxis, Pulmagen Therapeutics, Regeneron Pharmaceuticals, Revalesio, RSPR Pharma AB, SAMA Pharmaceuticals, Sanofi, Skyepharma, SolAeroMed, Stallergenes, Sterna Biologicals, Synairgen, Theron Pharmaceuticals, UCB Pharma, Vectura, Verona Pharma, and Whanin Pharmaceutical.
Segmentation by type of treatment and analysis of the asthma therapeutics market
During 2015, the preventive medications segment accounted for about 65% of the total market share and dominated this market. These medications are also called controller medications and help in the prevention of asthma attacks on a long-term basis. The continuous use of these medications results in less inflamed airways and controls the chronic symptoms of asthma. As a result, these are an essential treatment for most asthma patients and will have a constant demand in the next four years as well.
Segmentation by route of administration and analysis of the asthma therapeutics market
Since the onset of action is quick with systemic and local effect by inhalation, this mode of administration will account for major shares of the market and dominate the asthma treatment drugs industry throughout the forecast period. Drug administration by this mode happens in a phased manner, and many of the pipeline products for the treatment of asthma are also being developed for administering via inhalation.
Key questions answered in the report include
What will the market size and the growth rate be in 2020?
What are the key factors driving the global asthma therapeutics market?
What are the key market trends impacting the growth of the global asthma therapeutics market?
What are the challenges to market growth?
Who are the key vendors in the global asthma therapeutics market?
What are the market opportunities and threats faced by the vendors in the global asthma therapeutics market?
Trending factors influencing the market shares of the Americas, APAC, and EMEA.
What are the key outcomes of the five forces analysis of the global asthma therapeutics market
Technavio also offers customization on reports based on specific client requirement.